Should We Perform Repeated Re-Biopsy for the Detection of T790M Mutation?

Epidermal growth factor receptor (EGFR) T790M mutations have been detected in the second or third rebiopsy, even if the T790M mutation was not identified in the first rebiopsy. This meta-analysis investigated the EGFR T790M mutation detection rates and its additional advantages with repeated rebiops...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research and treatment 2023, 55(4), , pp.1190-1197
Main Authors: Kim, Saerom, Kim, Soo Han, Kim, Jinmi, Kim, Mi-Hyun, Lee, Min Ki, Eom, Jung Seop
Format: Article
Language:English
Subjects:
Original
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epidermal growth factor receptor (EGFR) T790M mutations have been detected in the second or third rebiopsy, even if the T790M mutation was not identified in the first rebiopsy. This meta-analysis investigated the EGFR T790M mutation detection rates and its additional advantages with repeated rebiopsies. We searched through the PubMed and EMBASE databases up to June 2022. Studies reporting rebiopsy to identify the EGFR T790M mutation in case of disease progression among patients with advanced non-small cell lung cancer (NSCLC) and multiple rebiopsies were included. The quality of the included studies was checked using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Eight studies meeting the eligibility criteria, reporting 1031 EGFR mutation-positive patients were selected. The pooled EGFR T790M mutation detection rate of the first and repeated rebiopsies were 0.442 (95% confidence interval [CI], 0.411-0.473; I2=84%; p
ISSN:1598-2998
2005-9256
DOI:10.4143/crt.2023.320